Effect of adipose tissue-derived stem cells therapy on clinical response in patients with primary Sjogren’s syndrome

Abstract

The purpose of this trial was to clinically assess the effect and safety of Adipose Tissue-derived Stem Cells (ADSCs) treatment on primary Sjogren’s Syndrome (pSS). In this 6-month randomized, triple-blind, placebo-controlled clinical trial, pSS patients were randomly assigned to two groups. After demographic characteristics and clinical examination were achieved, local injection of ADSCs into bilateral glands was performed with patients in ADSCs group (n = 35) and placebo solution was used for another group (n = 39) at three time points. Patients were followed up at 1-, 3- and 6-month. At each visit, studies of clinical and laboratory outcomes, as well as subjective symptoms, were conducted. A total of 74 subjects who met the including criteria were allocated in two groups and eventually 64 subjects (86.5%) completed the treatments and the follow-up assessments. Secretion of salivary and lachrymal glands were significantly improved in 3-month (P < 0.05). A great improvement of European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index (ESSDAI) was found after ADSCs treatment with intergroup comparison from baseline to follow-up (P < 0.05). There is also a significant difference of European Alliance of Associations for Rheumatology SS Patient Reported Index (ESSPRI) between the two groups in the follow-up (P < 0.05). A significant abatement of IgG, IgM, C3, C4 and ESR between two groups was observed in part of follow-up time points (P < 0.05). The ADSCs therapy can provide relief of oral and eye’s dryness in our trial in a short time and has potential improvement of subjective and systemic syndromes of pSS.

Update zum Sjögren-Syndrom: Diagnostik & Therapie

“…Zudem wurde eine signifikante Reduktion des ESSDAI im Vergleich zu Placebo gesehen [46]. Die Methodik der Studie ließ allerdings noch manche Frage offen und es wird [47]. Ein weiterer effektiver Einsatz wurde für die Therapie einer refraktären schweren thrombotisch thrombozytopenen Purpura nach frustranem Einsatz von Glukokor-tikoiden, Ciclosporin, Rituximab und intravenösen Immunglobulinen beschrieben [48].…”